Published in J Clin Psychiatry on September 01, 2008
Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend (2010) 1.20
Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry (2012) 1.04
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl) (2012) 0.97
Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace. Adolesc Psychiatry (Hilversum) (2013) 0.89
Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacology (Berl) (2010) 0.80
The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat. Psychopharmacology (Berl) (2010) 0.79
Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry (2004) 2.84
Drug interactions at GABA(A) receptors. Prog Neurobiol (2002) 2.02
Anticipation of monetary and social reward differently activates mesolimbic brain structures in men and women. Soc Cogn Affect Neurosci (2009) 1.72
Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry (2008) 1.53
Oxytocin influences processing of socially relevant cues in the ventral tegmental area of the human brain. Biol Psychiatry (2013) 1.53
Dissociation of neural networks for anticipation and consumption of monetary and social rewards. Neuroimage (2009) 1.49
Enhancement of atomoxetine serum levels by co-administration of paroxetine. Int J Neuropsychopharmacol (2007) 1.44
Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry (2005) 1.41
Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology (2002) 1.35
Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci (2008) 1.29
The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology (2008) 1.16
Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. J Nucl Med (2005) 1.15
The thalamus as the generator and modulator of EEG alpha rhythm: a combined PET/EEG study with lorazepam challenge in humans. Neuroimage (2004) 1.14
Asymmetry in dopamine D(2/3) receptors of caudate nucleus is lost with age. Neuroimage (2006) 1.04
'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigation. Hum Brain Mapp (2007) 1.03
Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J Neurosci (2007) 1.02
Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study. Neurobiol Aging (2008) 1.00
Brain imaging research: does the science serve clinical practice? Int Rev Psychiatry (2007) 0.98
Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proc Natl Acad Sci U S A (2012) 0.94
Acute alcohol effects on neuronal and attentional processing: striatal reward system and inhibitory sensory interactions under acute ethanol challenge. Neuropsychopharmacology (2004) 0.94
Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage (2006) 0.93
In vivo evidence of deep brain stimulation-induced dopaminergic modulation in Tourette's syndrome. Biol Psychiatry (2011) 0.92
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int J Neuropsychopharmacol (2006) 0.91
Bithalamical deep brain stimulation in tourette syndrome is associated with reduction in dopaminergic transmission. Biol Psychiatry (2009) 0.90
The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations. J Cereb Blood Flow Metab (2011) 0.89
In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine receptors. Bioorg Med Chem (2007) 0.88
Impaired sleep quality and sleep duration in smokers-results from the German Multicenter Study on Nicotine Dependence. Addict Biol (2012) 0.87
Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol (2005) 0.87
Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit (2004) 0.87
Human dopamine receptor D2/D3 availability predicts amygdala reactivity to unpleasant stimuli. Hum Brain Mapp (2010) 0.87
Neural evidence for an association between social proficiency and sensitivity to social reward. Soc Cogn Affect Neurosci (2013) 0.86
Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J Clin Psychopharmacol (2008) 0.85
PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity. J Cereb Blood Flow Metab (2005) 0.85
Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study. Biol Psychiatry (2011) 0.84
The German multi-centre study on smoking-related behavior-description of a population-based case-control study. Addict Biol (2011) 0.83
High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol (2004) 0.83
Surrogate markers for cerebral blood flow correlate with [¹⁸F]-fallypride binding potential at dopamine D(2/3) receptors in human striatum. Synapse (2013) 0.83
Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Int J Neuropsychopharmacol (2010) 0.82
Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother (2013) 0.82
The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging (2004) 0.82
Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. Neuroimage (2008) 0.82
Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers. Hum Psychopharmacol (2010) 0.82
Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol (2010) 0.81
The impact of dopamine on aggression: an [18F]-FDOPA PET Study in healthy males. J Neurosci (2013) 0.81
Elevated [(18)F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease. Neuroimage (2009) 0.81
Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. Int J Neuropsychopharmacol (2012) 0.81
Opioid receptor PET reveals the psychobiologic correlates of reward processing. J Nucl Med (2008) 0.81
Remission of drug-induced hepatitis after switching from risperidone to paliperidone. Am J Psychiatry (2010) 0.81
P50 sensory gating and smoking in the general population. Addict Biol (2011) 0.81
Increased turnover of dopamine in caudate nucleus of detoxified alcoholic patients. PLoS One (2013) 0.80
Effects of antipsychotic treatment on cognition in healthy subjects. J Psychopharmacol (2012) 0.80
Dopamine D2/D3 receptor availability and venturesomeness. Psychiatry Res (2011) 0.80
Tiagabine does not attenuate alcohol-induced activation of the human reward system. Psychopharmacology (Berl) (2007) 0.79
Functional polymorphism in the neuropeptide Y gene promoter (rs16147) is associated with serum leptin levels and waist-hip ratio in women. Ann Nutr Metab (2013) 0.79
The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. Eur Psychiatry (2008) 0.79
Anterior limbic alpha-like activity: a low resolution electromagnetic tomography study with lorazepam challenge. Clin Neurophysiol (2005) 0.78
Genetic variation in the neuropeptide Y gene promoter is associated with increased risk of tobacco smoking. Eur Addict Res (2012) 0.78
The role of 5-HT in response inhibition and re-engagement. Eur Neuropsychopharmacol (2013) 0.78
Lack of association of a functional catechol-O-methyltransferase gene polymorphism with risk of tobacco smoking: results from a multicenter case-control study. Nicotine Tob Res (2013) 0.77
Prolactin secretion is not a core dimension of "atypicality". Psychopharmacology (Berl) (2002) 0.77
Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid. J Clin Psychiatry (2015) 0.77
Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations? Int Clin Psychopharmacol (2016) 0.76
Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. J Clin Psychopharmacol (2016) 0.76
Interaction Between Risperidone, Venlafaxine, and Metronidazole: An Unknown Thread. J Clin Psychopharmacol (2016) 0.76
Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. Psychopharmacology (Berl) (2014) 0.76
Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine. Clin Neuropharmacol (2009) 0.76
Altered benzodiazepine receptor sensitivity in alcoholism: a study with fMRI and acute lorazepam challenge. Psychiatry Res (2007) 0.76
Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol (2011) 0.76
Lamotrigine in pregnancy - therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. Int Clin Psychopharmacol (2015) 0.75
Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. Psychopharmacology (Berl) (2011) 0.75
[Radiopharmaceutical strategies and clinical applications. Diagnosis of CNS disease with PET as well as SPECT]. Pharm Unserer Zeit (2005) 0.75
Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone. J Clin Psychopharmacol (2016) 0.75
[German Society of Nuclear Medicine procedure guideline on beta-amyloid brain PET imaging]. Nuklearmedizin (2016) 0.75
Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a nonfatal overdose during a suicide attempt. J Clin Psychopharmacol (2014) 0.75
Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt. Int J Neuropsychopharmacol (2009) 0.75
Neuropsychological correlates of transcription factor AP-2Beta, and its interaction with COMT and MAOA in healthy females. Neuropsychobiology (2013) 0.75
Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient. J Clin Psychiatry (2011) 0.75
Comparison of Clomethiazole and Diazepam in the Treatment of Alcohol Withdrawal Syndrome in Clinical Practice. Eur Addict Res (2017) 0.75
Measuring citalopram in blood and central nervous system: revealing a distribution pattern that differs from other antidepressants. Int Clin Psychopharmacol (2016) 0.75
Distribution pattern of mirtazapine and normirtazapine in blood and CSF. Psychopharmacology (Berl) (2014) 0.75
Suicide attempt during late pregnancy with quetiapine: nonfatal outcome despite severe intoxication. J Clin Psychopharmacol (2015) 0.75